Myomaker Bio, a Loughborough University spin-out, has launched a world-first lab-grown human muscle platform for drug developers. Boehringer Ingelheim...
Lire la suiteMSK researchers have reported encouraging long-term follow-up results from a small phase 1 trial of a personalised mRNA vaccine...
Lire la suiteTransgene has completed patient randomisation in the phase 2 part of its phase 1/2 TG4050 trial in head and...
Lire la suiteKainova Therapeutics has dosed the first patient in Europe in its DOMISOL phase 1/2 trial of DT 7012, expanding...
Lire la suiteBiogen has secured US FDA approval for a high dose Spinraza regimen for spinal muscular atrophy. Viridian Therapeutics has...
Lire la suiteDNA Script is expanding access to its SYNTAX platform across Latin America, South Korea and Japan through new distribution...
Lire la suite